Cargando…

CD169 (Siglec-1) as a Robust Human Cell Biomarker of Toll-Like Receptor 9 Agonist Immunotherapy

Immunotherapy is a promising therapeutic area in cancer and chronic viral infections. An important component of immunotherapy in these contexts is the activation of innate immunity. Here we investigate the potential for CD169 (Siglec 1) expression on monocytes to serve as a robust biomarker for acti...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lende, Stine Sofie Frank, Pahus, Marie Høst, Monrad, Ida, Olesen, Rikke, Mahr, Anna R., Vibholm, Line K., Østergaard, Lars, Søgaard, Ole Schmeltz, Andersen, Anna Halling Folkmar, Denton, Paul W., Tolstrup, Martin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Cellular and Infection Microbiology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9294151/ https://www.ncbi.nlm.nih.gov/pubmed/35865810 http://dx.doi.org/10.3389/fcimb.2022.919097

Ejemplares similares

Comparable human reconstitution following Cesium-137 versus X-ray irradiation preconditioning in immunodeficient NOG mice
por: Andersen, Anna Halling Folkmar, et al.
Publicado: (2020)

Long-term humoral and cellular immunity after primary SARS-CoV-2 infection: a 20-month longitudinal study
por: Hvidt, Astrid Korning, et al.
Publicado: (2023)

SARS-CoV-2 elicits robust adaptive immune responses regardless of disease severity
por: Nielsen, Stine SF, et al.
Publicado: (2021)

Effect of Age on Innate and Adaptive Immunity in Hospitalized COVID-19 Patients
por: Cham, Lamin B., et al.
Publicado: (2021)

SARS-CoV-2 persistence is associated with antigen-specific CD8 T-cell responses
por: Vibholm, Line K, et al.
Publicado: (2021)

Nanobody‐mediated complement activation to kill HIV‐infected cells
por: Pedersen, Maria Lange, et al.
Publicado: (2023)

The Potential of Long-Acting, Tissue-Targeted Synthetic Nanotherapy for Delivery of Antiviral Therapy Against HIV Infection
por: Halling Folkmar Andersen, Anna, et al.
Publicado: (2020)

Immune checkpoints and the HIV-1 reservoir: proceed with caution
por: Olesen, Rikke, et al.
Publicado: (2016)

Treatment of HIV-Infected Individuals with the Histone Deacetylase Inhibitor Panobinostat Results in Increased Numbers of Regulatory T Cells and Limits Ex Vivo Lipopolysaccharide-Induced Inflammatory Responses
por: Brinkmann, Christel Rothe, et al.
Publicado: (2018)

Myeloid CD169/Siglec1: An immunoregulatory biomarker in viral disease
por: Herzog, Silva, et al.
Publicado: (2022)

The Use of Toll-Like Receptor Agonists in HIV-1 Cure Strategies
por: Martinsen, Janne Tegder, et al.
Publicado: (2020)

Fimepinostat, a novel dual inhibitor of HDAC and PI3K, effectively reverses HIV-1 latency ex vivo without T cell activation
por: Gunst, Jesper D, et al.
Publicado: (2019)

Discovery of neutralizing SARS-CoV-2 antibodies enriched in a unique antigen specific B cell cluster
por: Lende, Stine Sofie Frank, et al.
Publicado: (2023)

Peripheral prion disease pathogenesis is unaltered in the absence of sialoadhesin (Siglec-1/CD169)
por: Bradford, Barry M, et al.
Publicado: (2014)

A Protective Role for the Lectin CD169/Siglec-1 against a Pathogenic Murine Retrovirus
por: Uchil, Pradeep D., et al.
Publicado: (2019)

SIGLEC1 (CD169): a marker of active neuroinflammation in the brain but not in the blood of multiple sclerosis patients
por: Ostendorf, Lennard, et al.
Publicado: (2021)

Persistent Severe Acute Respiratory Syndrome Coronavirus 2 Infection in Immunocompromised Host Displaying Treatment Induced Viral Evolution
por: Monrad, Ida, et al.
Publicado: (2021)

Porcine Sialoadhesin (CD169/Siglec-1) Is an Endocytic Receptor that Allows Targeted Delivery of Toxins and Antigens to Macrophages
por: Delputte, Peter L., et al.
Publicado: (2011)

Interferon-Inducible Mechanism of Dendritic Cell-Mediated HIV-1 Dissemination Is Dependent on Siglec-1/CD169
por: Puryear, Wendy Blay, et al.
Publicado: (2013)

SIGLEC1 (CD169) is a sensitive biomarker for the deterioration of the clinical course in childhood systemic lupus erythematosus
por: von Stuckrad, Sae Lim, et al.
Publicado: (2020)

CD169/SIGLEC1 is expressed on circulating monocytes in COVID-19 and expression levels are associated with disease severity
por: Doehn, Jan-Moritz, et al.
Publicado: (2021)

In vivo imaging of retrovirus infection reveals a role for Siglec-1/CD169 in multiple routes of transmission
por: Haugh, Kelsey A, et al.
Publicado: (2021)

Single cell analysis reveals a subset of cytotoxic-like plasmacytoid dendritic cells in people with HIV-1
por: Cham, Lamin B., et al.
Publicado: (2023)

Broad activation of latent HIV-1 in vivo
por: Barton, Kirston, et al.
Publicado: (2016)

Sialoadhesin (CD169/Siglec-1) is an extended molecule that escapes inhibitory cis-interactions and synergizes with other macrophage receptors to promote phagocytosis
por: Klaas, Mariliis, et al.
Publicado: (2023)

The TLR9 agonist MGN1703 triggers a potent type I interferon response in the sigmoid colon
por: Krarup, Astrid Raaby, et al.
Publicado: (2017)

Strategies for enhancing CAR T cell expansion and persistence in HIV infection
por: Rothemejer, Frederik Holm, et al.
Publicado: (2023)

Interaction of the European genotype porcine reproductive and respiratory syndrome virus (PRRSV) with sialoadhesin (CD169/Siglec-1) inhibits alveolar macrophage phagocytosis
por: De Baere, Miet I, et al.
Publicado: (2012)

Activation of Latent Human Immunodeficiency Virus by the Histone Deacetylase Inhibitor Panobinostat: A Pilot Study to Assess Effects on the Central Nervous System
por: Rasmussen, Thomas A., et al.
Publicado: (2015)

Comparison of HDAC inhibitors in clinical development: Effect on HIV production in latently infected cells and T-cell activation
por: Rasmussen, Thomas Aagaard, et al.
Publicado: (2013)

Endotoxemia Is Associated with Altered Innate and Adaptive Immune Responses in Untreated HIV-1 Infected Individuals
por: Bukh, Anne Roslev, et al.
Publicado: (2011)

Using animal models to overcome temporal, spatial and combinatorial challenges in HIV persistence research
por: Denton, Paul W., et al.
Publicado: (2016)

Impacts of HIV Cure Interventions on Viral Reservoirs in Tissues
por: Denton, Paul W., et al.
Publicado: (2019)

Siglec Ligands
por: Gonzalez-Gil, Anabel, et al.
Publicado: (2021)

Administration of a Toll-Like Receptor 9 Agonist Decreases the Proviral Reservoir in Virologically Suppressed HIV-Infected Patients
por: Winckelmann, Anni A., et al.
Publicado: (2013)

Impact of a TLR9 agonist and broadly neutralizing antibodies on HIV-1 persistence: the randomized phase 2a TITAN trial
por: Gunst, Jesper D., et al.
Publicado: (2023)

Molecular cloning of porcine Siglec-3, Siglec-5 and Siglec-10, and identification of Siglec-10 as an alternative receptor for porcine reproductive and respiratory syndrome virus (PRRSV)
por: Xie, Jiexiong, et al.
Publicado: (2017)

TLR9 agonist MGN1703 enhances B cell differentiation and function in lymph nodes
por: Schleimann, Mariane H., et al.
Publicado: (2019)

Coevolution of Siglec-11 and Siglec-16 via gene conversion in primates
por: Hayakawa, Toshiyuki, et al.
Publicado: (2017)

Redirector of Vaccine-induced Effector Responses (RoVER) for specific killing of cellular targets
por: Konrad, Christina V., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_ba9thlnrou38msi9r4t6uu04nc